ASKA Pharmaceutical Co., Ltd. Stock Japan Exchange
Stocks
4514
JP3541200006
Pharmaceuticals
OTC Markets Traded| Market Cap | 60.51B 386M 335M 313M 288M 542M 36.79B 552M 3.69B 1.45B 18.35B 1.45B 1.42B | P/E 2027 * |
13x | P/E 2028 * | 11x |
|---|---|---|---|---|---|
| Enterprise Value | 60.51B 386M 335M 313M 288M 542M 36.79B 552M 3.69B 1.45B 18.35B 1.45B 1.42B | EV / Sales 2027 * |
0.83x | EV / Sales 2028 * | 0.81x |
| Free-Float |
63.84% | Yield 2027 * |
3.05% | Yield 2028 * | 3.28% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tomohito Nagao
CEO | Chief Executive Officer | - | - |
Sota Yamaguchi
PSD | President | 42 | 24/06/2025 |
Kiyohiko Tamura
ADM | Chief Administrative Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 24/06/2025 | |
Atsushi Maruo
BRD | Director/Board Member | 67 | 01/04/2021 |
Sota Yamaguchi
BRD | Director/Board Member | 42 | 01/04/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -4.29% | - | - | 386M | |
| -2.39% | -6.36% | +47.10% | +149.66% | 1T | |
| -0.76% | -4.34% | +52.04% | +49.09% | 613B | |
| -2.33% | -4.60% | +25.55% | +64.44% | 433B | |
| +0.68% | -1.14% | +38.47% | +33.36% | 350B | |
| -1.66% | -3.13% | +32.18% | +39.79% | 292B | |
| -8.96% | -10.77% | +3.57% | +5.50% | 239B | |
| -1.37% | -7.41% | -2.10% | -43.67% | 206B | |
| -1.63% | +0.69% | +27.62% | +64.23% | 204B | |
| +0.72% | +0.48% | +15.88% | +73.64% | 163B | |
| Average | -1.38% | -3.88% | +26.70% | +48.45% | 388.94B | |
| Weighted average by Cap. | -0.93% | -4.34% | +34.73% | +70.96% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 73.12B 466M 405M 378M 347M 655M 44.46B 667M 4.46B 1.75B 22.17B 1.75B 1.71B | 74.96B 478M 416M 388M 356M 671M 45.57B 683M 4.57B 1.79B 22.73B 1.8B 1.76B |
| Net income | 4.67B 29.78M 25.88M 24.16M 22.18M 41.83M 2.84B 42.56M 285M 112M 1.42B 112M 109M | 5.52B 35.23M 30.62M 28.59M 26.25M 49.49M 3.36B 50.35M 337M 132M 1.67B 132M 129M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
